SNORD10: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD10

NCBI ID: G652966

SNORD10

Other Name(s): small nucleolar RNA, C/D box 10 | mgU6-77 | Small nucleolar RNA, C/D box 10

SNORD10: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the key classes of snRNA is the C/D box snRNA (CISN), which is characterized by the presence of a characteristic C/D box motif. C/D box snRNA is an abundant class of snRNA molecules, and many have been identified as potential drug targets or biomarkers. In this article, we focus on SNORD10, a C/D box snRNA that has been shown to play important roles in various cellular processes and is potential drug target.

SNORD10 is a 22-nt RNA molecule that contains a unique C/D box motif. The C/D box is a conserved region that is found in the middle of the molecule and consists of a series of aromatic and hydrophobic amino acids. The C /D box is thought to play a structural role in the regulation of snRNA stability and localization to the nucleus.

SNORD10 has been shown to be involved in a variety of cellular processes, including DNA replication, gene expression, and cell growth. For example, studies have shown that SNORD10 is involved in the regulation of DNA replication, specifically in the proofreading of DNA duplexes accuracy. In addition, SNORD10 is also related to gene expression. For example, studies have found that SNORD10 can regulate gene expression and thereby participate in cell differentiation and tumorigenesis.

In addition, SNORD10 is also related to cell growth. Studies have shown that SNORD10 can participate in cell growth and cell cycle regulation, thereby participating in tumor growth and progression.

SNORD10 has also been shown to be a potential drug target. Studies have shown that SNORD10 can interact with drugs and regulate drug metabolism and clearance. For example, one study found that SNORD10 can increase drug clearance, thereby improving drug effectiveness. In addition, some anti-tumor drugs (such as taxanes) have been shown to inhibit the activity of SNORD10, thereby increasing the efficacy of the drugs.

In addition to being a drug target, SNORD10 is also a potential biomarker. Studies have shown that the expression level of SNORD10 can reflect the aggressiveness and growth rate of tumors and thus the effectiveness of tumor treatment. In addition, the expression level of SNORD10 can also reflect cell cycle status and DNA damage, thereby serving as a biomarker of cell cycle and DNA damage.

The discovery and functional study of SNORD10 provides us with a new perspective. We can use SNORD10 as a drug target or biomarker to study the pathogenesis and treatment strategies of tumors. Future research can focus on the following aspects:

1. In-depth study of the functions of SNORD10, including its role in DNA replication, gene expression and cell growth.
2. Explore the interactions of SNORD10, including its interactions with drugs, substrates, and other molecules.
3. Study the role of SNORD10 in tumors, including its impact on tumor invasiveness, growth rate and cell cycle.
4. Explore the potential and application prospects of SNORD10 as a drug target or biomarker.

SNORD10 is a C/D box snRNA with unique functions, which plays an important role in DNA replication, gene expression and cell growth. By deeply studying the function of SNORD10, we can reveal its potential role in tumor pathogenesis and treatment strategies, and provide better treatment options for tumor patients.

Protein Name: Small Nucleolar RNA, C/D Box 10

The "SNORD10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets